SUMMT has shown for the first time that a drug can reduce major heart failure clinical outcomes in patients with heart ...

CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking ...

Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...

Tirzepatide by Eli Lilly reduces heart failure risk in adults with HFpEF and obesity, showing promising results for both ...

For patients with obesity and prediabetes, three years of tirzepatide yields substantial and sustained weight reductio ...

The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

"Obesity contributes to worsening heart failure, and while tirzepatide causes considerable weight loss, research is lacking ...

On Saturday, Eli Lilly And Co (NYSE:LLY) released detailed results from the SUMMIT Phase 3 trial showing tirzepatide reduced ...

HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...

Payers and employers have tightened access to the glucagon-like peptide-1 receptor agonist class once these therapies became ...